Steatotic Liver Disease in Austria - Prospective Registry With Biobank

Steatotic liver disease (SLD) is the most common chronic liver disease and is associated with an increased risk of liver-related complications, cardiovascular disease, and malignancies. However, comprehensive prospective data on the clinical characteristics, disease progression, and management of patients with SLD in Austria remain limited. The SLD-AT study is a multicenter, prospective, observational registry with an associated biobank aiming to characterize patients with suspected or confirmed SLD in Austria. The registry will collect longitudinal clinical, laboratory, imaging, and treatment-related data to investigate disease progression, clinical outcomes, and the prognostic value of non-invasive tests and biomarkers. The study aims to enroll approximately 20,000 participants over a planned duration of 15 years.

Inclusion Criteria: * 1\. Age 18-100 years. * 2\. Suspected steatotic liver disease (SLD), defined by at least one of the following criteria: * Suspected SLD based on previous medical findings. * Evidence of hepatic steatosis assessed by, Controlled attenuation parameter (CAP), Ultrasound, Magnetic resonance imaging (MRI), or Liver histology * Suspected advanced liver fibrosis assessed by Vibration-controlled transient elastography (VCTE; ≥8 kPa), Ultrasound, Magnetic resonance elastography (MRE), or Liver histology * Elevated liver enzymes (AST, ALT, and/or GGT) within 6 months prior to enrollment. * 3\. Written informed consent to participate in the registry. Exclusion Criteria: * Withdrawal of written informed consent. * Diagnosis of any of the following active chronic liver diseases: * Chronic hepatitis B * Chronic hepatitis C * Autoimmune or cholestatic liver disease * Genetic liver disease * Current diagnosis of alcohol-associated hepatitis. * Current decompensated liver cirrhosis.